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The book Low Molecular Weight Heparin Therapy pro-
vides a unique reference for the serious student of antico-
agulant therapy. The editors and authors have provided a
text in which the major studies in particular topics have
been summarized one by one, and then expert commen-
tary has been given at the end of each section. This com-
mentary summarizes the opinion of the experts on the
material discussed and their own personal biases concern-
ing the topic of interest. The commentators are interna-
tional experts in the field of coagulation biology. In almost
all instances, the commentary includes not only discussions
about low molecular weight heparin (LMWH) therapy but
also anticoagulant therapy in general. One of the strengths
of this book is its ability, through its commentaries, to put
into proper perspective not only what is known, but impor-
tantly, what is still unknown concerning LMWH.
As appropriate for such a book, more than two thirds of
the work is concerned with venous thromboembolism pro-
phylaxis and treatment, the most widely studied areas of
LMWH. The book opens with a description of the market-
ed LMWHs and follows with a discussion of chemical and
biological properties of various LMWH preparations and
their mode of action. I found this discussion very informa-
tive, and it reinforced the concept that the anti-Xa activity
for each individual LMWH is of limited use in judging the
pharmacologic properties of the drug. The various LMWH
preparations must be evaluated on their own merits and
should not be considered one and the same drug.
The two longest sections follow: the first is on prophy-
laxis of venous thromboembolism, and the second is on the
treatment of venous thromboembolism. Commentaries,
which are particularly informative, include those concerning
orthopedic surgery and trauma venous thrombosis prophy-
laxis, and the discussion on the “International Concensus
Statement” for venous thromboembolism prophylaxis is an
excellent overview on the current state of the art. The treat-
ment aspects associated with the use of LMWH are well
covered, and the commentaries provide not only a summa-
ry of the most up-to-date knowledge about LMWH, but
also guidelines for necessary future studies.
The remainder of the book covers topics less well
known, from anti-Xa monitoring to the use of LMWH in
indications such as arterial thrombosis, including vascular
and coronary indications, pregnancy, and pediatrics. Other
topics include the decreased incidence of osteoporosis with
LMWH compared with standard unfractionated heparin,
the decreased incidence of heparin-induced thrombocy-
topenia with LMWH, and the ability for LMWH to be
reversed by protamine sulfate. The book ends with a dis-
cussion of meta-analyses that have evaluated LMWH
(although throughout the book, meta-analyses are down-
played because of the differences in various LMWH prepa-
rations) and a look to the future. A scholarly description of
the present position of LMWH in various clinical syn-
dromes and the drugs that are likely to challenge LMWH
in the future for these syndromes concludes.
This is an unusual book that combines aspects of a
reference guide and a forum for discussion by experts in
the world concerning a wide variety of topics for which
LMWH has been advocated. This is not a book in which
a busy clinician will easily find a “cookbook” approach
to the use and dosages of LMWH. However, it is clear-
ly a must for those clinician scientists who wish to exam-
ine the data from which recommendations for the use of
LMWH have been derived and who wish to have inter-
national experts discuss the data from their own unique
perspectives.
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Management of Acute Stroke, edited by Ashfaz Shuaib
and Larry Goldstein, provides a critical review of current
stroke evaluation methods and treatment studies. Unlike
other recently produced texts on stroke management, it
emphasizes broad treatment strategies rather than the
management of specific disease processes. The relatively
short chapters and frequent use of tables help to make it a
very readable textbook.
The first half of the book addresses prehospital and hos-
pital evaluation of the patient with acute stroke and includes
a chapter each on the common causes of stroke in children,
young adults, and elderly adults. Certain chapters in this
section, especially the laboratory investigations in acute
stroke, provide concise, practical information. Those chap-
ters reviewing the causes of stroke in different age groups
are packed with lists and, perhaps because so few chapters
are allocated for these subjects, provide a more superficial
treatment of each topic. Although included in this section,
the chapter examining the pathophysiology of ischemic
brain damage provides an excellent preview of the treatment
section and fits better in the second half of the book.
The strongest chapters of this book are those evaluating
the myriad stroke treatment trials encompassing stroke pre-
vention, acute treatment, and rehabilitation, which are found
in the second half of the book. The chapters discussing
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